KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two upcoming investor conferences:

• Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 a.m. EST
• Jefferies London Healthcare Conference on November 16, 2021, at 5:40 p.m. GMT

Live webcasts of the presentations will be available on www.kalvista.com, with archives accessible for 30 days post-event. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences:

• Stifel 2021 Virtual Healthcare Conference on Monday, November 15, 2021 at 9:20 a.m. EST
• Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 5:40 p.m. GMT

A live webcast of the presentations will be available on the Company’s website at www.kalvista.com. An archive of the presentations will be available on KalVista’s website for 30 days following the presentations.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints. KVD824 is in development for prophylactic treatment of HAE with the Phase 2 KOMPLETE clinical trial underway. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment of HAE for patients. In DME, an intravitreally administered plasma kallikrein inhibitor, called KVD001, has completed a Phase 2 clinical trial.

For more information, please visit www.kalvista.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005252/en/

KalVista Pharmaceuticals, Inc.

Leah Monteiro

Senior Director, Corporate Communications & Investor Relations

857-999-0808

leah.monteiro@kalvista.com

Source: KalVista Pharmaceuticals, Inc.

FAQ

What are the dates for KalVista Pharmaceuticals' upcoming investor conferences?

KalVista Pharmaceuticals will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies London Healthcare Conference on November 16, 2021.

What is the stock symbol for KalVista Pharmaceuticals?

The stock symbol for KalVista Pharmaceuticals is KALV.

Where can I watch the KalVista Pharmaceuticals presentations?

Live webcasts of the KalVista Pharmaceuticals presentations will be available on their website, www.kalvista.com.

What is KalVista Pharmaceuticals focused on?

KalVista Pharmaceuticals is focused on the discovery and development of small molecule protease inhibitors for diseases with significant unmet medical needs.

What therapies are KalVista Pharmaceuticals developing?

KalVista is developing KVD900 for acute hereditary angioedema attacks and KVD824 for prophylactic treatment of hereditary angioedema.